US Patent Issued to Beth Israel Deaconess Medical Center, Board of Regents of the University of Nebraska on July 29 for "Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis" (Massachusetts, Nebraska Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,372,530, issued on July 29, was assigned to Beth Israel Deaconess Medical Center Inc. (Boston) and Board of Regents of the University of Nebraska (Lincoln, Neb.).

"Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis" was invented by Towia Aron Libermann (Chestnut Hill, Mass.), Michelle Lai (Brookline, Mass.), Nezam Hassan Afdhal (Charlestown, Mass.), Hasan Huseyin Otu (Lincoln, Neb.) and Simon Thomas Dillon (Rockport, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for diagnosing non-alcoholic steatohepatitis (NASH) and NASH with or without advanced liver fibrosis in a subject are prov...